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Summary
Objectives To test the hypothesis that the USA healthcare system was
superior to the NHS and 17 other Western countries in reducing feasible
mortality rates over the period 1979–2005.
Design Economic inputs into healthcare, GDP health expenditure
(GDPHE) were compared with clinical outputs, i.e. total ‘adult’ (15–74
years) and ‘older’ (55–74 years) mortality rates based upon three-year
average mortality rates for 1979–81 vs. 2003–2005. A cost-effective ratio
was calculated by dividing average GDPHE into reduced mortality rates
over the period.
Setting Nineteen Western countries’ mortality rates compared
between 1979–2005.
Participants Mortality of people by age and gender.
Main outcome measures A cost-effective ratio to measure
efﬁciency and effectiveness of healthcare systems in reducing mortality
rates. Chi-square tested any differences between the USA, UK and other
Western countries.
Results Input: The USA had the highest current and average GDPHE;
the UK was 10th highest but joint 16th overall, still below the Western
countries’ average. Output: Every country’s mortality rate fell
substantially; but 15 countries reduced their mortality rates signiﬁcantly
more than the US, while UK ‘adult’ and ‘older’ mortality rates fell
signiﬁcantly more than 12 other countries. Cost-effectiveness: The USA
GDPHE: mortality rate ratio was 1:205 for ‘adults’ and 1:515 for ‘older’
people, 16 Western countries having bigger ratiosthan the US; the UK had
second greatestratios at1:593and 1:1595, respectively. The UK ratioswere
>20% larger than 14 other countries.
Conclusions In cost-effective terms, i.e. economic input versus clinical
output, the USA healthcare system was one of the least cost-effective in
reducing mortality rates whereas the UK was one of the most cost-
effective over the period.
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RESEARCH
1Introduction
The US presidential and mid-term elections
evoked considerable controversy about the
reforms of the American healthcare,
1 while
British visitors were struck by the frequent
mention of the apparent failings of the NHS. As
all healthcare systems are run by human beings,
there will imperfections and errors in most
1 but
the concerns expressed by the English Chief
Medical Ofﬁcer of the ‘need for safer surgery’
was seen as authoritative evidence of an
inadequate NHS.
2 However, in a recent
meta-analysis of studies mainly from North
America also concerned with ‘adverse events’ in
theatre,
3 the predominantly US results, when com-
pared with the Association of General Surgeons of
Great Britain & Ireland outcomes, were signiﬁ-
cantly worse.
4
Nonetheless, the protagonists of current US
healthcare were by inference suggesting that their
system is at least as good if not superior to others.
This led us to ask the question how cost-
effective and productively efﬁcient is the US
healthcare system, compared with the other
Western countries and the UK in particular?
The vast sums of moneyspent byevery Western
country on health, that is gross domestic product
health expenditure (GDPHE),
5 meansthe question
is relevant to every country.
To assess the different countries’ productive
efﬁciencyand cost-effectiveness of theirhealthcare
system we use a simple economic model. To deter-
mine cost-effectiveness, a nation’s GDPHE is used
asthe economic input, against the clinical outputs,
to examine how effective the nation was in redu-
cing all feasible ‘adult’ (15–74 years) and ‘older’
(55–74 years) mortality rates, feasibility within
the context of the current art and science of medi-
cine. Consequently, mortality rate is chosen as the
main clinical output because feasibly reducing
mortality is the ultimate goal of all health
systems. Indeed the British government believes
reducing cancer deaths in people <74years is a
reasonable goal,
6 so we examine all ‘adult’ (15–
74 years) and ‘older’ (55–74 years) people’s mor-
tality rates, the latter age band where the greatest
‘gains’ might be expected.
6–8
It is acknowledged that mortality is inﬂuenced
by other socioeconomic and policy factors rather
than just health expenditure.
9–13. Yet mortality
rate is a rationale comparative measure to
compare a nation’s healthcare, as the only way
to judge one’s own health system’s ‘output’ is to
assess it against other comparable Western
nations.
There are four null hypotheses from the period
1980–2005. Therewill be no statisticallysigniﬁcant
differences between the USA, the UK and the
other Western countries in:
1. reducing all ‘adult’ (15–74) mortality rates;
2. reducing ‘older’ (55–74) mortality rates;
3. USA GDPHE: reduced mortality rate ratios will
be as good as most other countries;
4. UK GDPHE: reduced mortality rate ratios will
not be as good as most of the other countries.
Methodology
Baseline and index years (1979–1981 vs.
2003–2005)
The index year of 2005 was chosen, as it is the
latest year American World Health Organization
(WHO) mortality datacan be uniformly compared
with other countries.
14 Annual mortality rates
vary slightly and to offset this three average mor-
tality rates are used, with the baseline 3 years of
1979–1981, contrasted with three-year index
years 2003–2005, to match the latest available
international GDHPE data.
5 The combined male
and female mortality rate of each country is
given in rates per million (pm).
14 The latest
Australia, Italy and Portugal data were for 2001–
2003, and for Canada and New Zealand 2002–
2004 so these countries’ mortality is contrasted
with the same years in the UK and USA. The
time difference of Belgium and Denmark’s latest
mortality rates, 1997 and 2001, was too great for
proper comparison and are excluded from the
study, leaving 17 Western countries to compare
with economic ‘inputs’ and clinical ‘outputs’
from the UK and USA.
Effectiveness: economic health inputs
GDPHE data from 1980 up to 2005 are the primary
economic input, given as total percentage of
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2GDPHE and the separate sources of ﬁnance,
‘Public’, from State and National taxes or insur-
ance, and ‘Private’, via personal or employers
insurance
5 from which an average GDPHE for
1980–2005 is calculated.
Effectiveness: clinical (mortality)
outcomes
Combined gender mortality rates per million (pm)
are extrapolated from WHO data
14 for the years
1979–81 and 2003–2005 and are shown in three
20-year age bands: 15–34, 35–54 and 55–
74years, from which an all ‘adult’ (15–74 years)
mortality rate is calculated.
USA and UK ‘adult’ (15–74) and ‘older’ (55–
74) mortality rates are compared with each of the
other countries, and chi-square tests are used to
determine any signiﬁcant differences between
them over the period. Standard deviations (s.d.)
for mortality rates are calculated: +1 or –1 s.d.
are considered clinically signiﬁcant.
Cost-effectiveness ratio
Cost-effectiveness is taken as the relation between
economic input and clinical output based upon a
calculation of a ratio of the average GDPHE and
the reduced mortality rate over the period. The
greater the ratio the more cost-effective is that
country’s reduction of mortality rate. It is recog-
nized that the value of 1% of GDP will vary
between countries, but it is a comparative
measure of a nation’s priority to healthcare. The
former Prime Minister Thatcher once said ‘we
can only have the services we can afford’.
15 Com-
paring nations’ GDPHE shows how much differ-
ent nations ‘afforded’.
To place these rates in a more ‘clinical’ context,
the numbers of reduced deaths are calculated for
the USA and UK if the current population’s
death rates had died at same rate as in 1979–1981.
Results
Economic inputs – GDPHE 1980–2005
Countries are ranked by the highest average GDP
over the period (1980–2005) (Table 1).
Total GDPHE: In 1980 the highest GDPHE per-
centages were in Sweden (9%), USA (8.8%) and
Germany (8.7%), the lowest being 5.3% in Spain
and 5.6% in both Portugal and the UK.
By the end of the period GDPHE had risen
in every country, except Ireland, the current
highest being the USA (15.3%), Switzerland
(11.6%) and France (11.1%), and the lowest being
Finland and Ireland (7.5%) and Japan (8%). The
Western countries current average of 9.7% is
above the UK’s 9.3%, which is 10th highest of
19 countries.
The highest average (1980–2005) total GDPHE
was led by the USA at 12.2%, Germany at 9.7%
and Switzerland at 9.3% with all Western
countries averaging 7.4%.
Spain was lowest at 6.8%, Japan at 7.0%, with
Finland, Ireland and the UK at 7.1%, all below
the average 7.4% of the other countries.
Sources of GDPHE: Only Greece (5.8%) and the
USA (8.4%) had higher ‘Private’ GDPHE than
‘Public’ funded GDPHE. However, it should be
noted that the USA ‘Public’ GDPHE of 6.9% was
higher than the average Western countries’
‘Public’ at 6.87%, being higher than eight other
countries’ ‘Public’ GDPHE.
The UK ‘Private’ GDPHE was lower than the
average GDPHE but its current ‘Public’ GDPHE
of 7.1% was higher than the average GDPHE of
the other countries.
Clinical outputs: reduced mortality rates
1980–2005
Table 2 presents total combined male and female
mortality rates per million (pm) of the population
between 1979–1981 and 2003–2005 ranked by the
highest current ‘adult’ (15–74) and ‘older’ (55–74)
mortality rates. The current and previous year’s
rank order are shown in column one.
‘Adult’ (15–74) mortality rate
Every country’s rates fell more than 27%, except
Portugal, which fell only 17%. Initially the three
highest ‘adult’ rates were in Ireland 10,374 pm,
Austria 9762 pm and the UK 9682 pm, with the
USA ﬁfth at9158 pm. The lowest were Switzerland
5651 pm, Spain 6499 pm and Japan 6782 pm.
Four countries’ ‘adult’ rates were 1 s.d. (1201
pm) above the mean 8236 pm: Ireland, Austria,
the UK and New Zealand; while Japan,
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3Switzerland and Spain were 1 s.d. below the
mean.
By 2003–2005 the USA ‘adult’ MR was highest
at 6660 pm, followed by Portugal 6483 pm,
Finland 5692 pm, with the UK falling from third
to ﬁfth highest at 5475 pm, and now within the
mean; the lowest being Japan 4182 pm,
Switzerland 4355 pm and Sweden 4373 pm. Cur-
rently only the USA and Portugal mortality rate
is 1 s.d. above the mean, and Japan, Sweden and
Switzerland 1 s.d below the mean.
‘Older’ (55–74) mortality rate
Initially, the three highest ‘older’ mortality rates
were Ireland 26,738 pm, the UK 24,961 pm and
New Zealand 24,203 pm; the USA was ﬁfth
highest at 22,199 pm.
The smallest reductions were in Portugal (18%)
and the USA (28%). The UK mortality rate fell
45%, only Ireland at 48% and Australia at 47%
had bigger declines, as the UK ‘older’ mortality
rate fell from second to sixth highest.
Initially, Ireland, the UK and New Zealand
were 1 s.d. above the mean (20,607 pm, 1 s.d. =
3505 pm) and Japan and Switzerland being 1 s.d.
below the mean. Currently only the USA and Por-
tugal are 1 s.d. above the mean (12,950 pm 1 s.d. =
1386 pm), the UK within the mean and again
Japan, Switzerland and Sweden now 1 s.d. below
the mean.
International comparisons
USA vs. other countries: Over the period only
Portugal had a signiﬁcantly lower reduction of
‘adult’ mortality rate than the USA (Table 3). Con-
versely, marked with
† in the table, 14 countries’
‘adult’ mortality rates had signiﬁcantly greater
reductions than the USA.
With regard to ‘older’ people, the USA mor-
tality rate declined signiﬁcantly more than
Table 1
Average and current GDP health expenditure (ranked by average 1980–2005 GDPHE)
Country
GDPHE
1980
Current GDPHE
Public
Current GDPHE
Private
Current Total
GDPHE
Total GDPHE
average 1980–2005
1 USA 8.8 6.9 8.4 15.3 12.2
2 Germany 8.7 8.2 2.5 10.7 9.7
3 Switzerland 7.4 6.9 4.0 11.6 9.3
4 Sweden 9.0 7.7 1.4 9.1 8.8
4 France 7.0 8.9 2.2 11.1 8.8
6 Canada 7.1 6.9 2.9 9.8 8.7
7 Netherlands 7.2 5.7 3.5 9.2 8.4
7 Greece 6.6 4.3 5.8 10.1 8.4
9 Australia 7.5 6.4 3.1 9.5 8.3
10 Italy 7.0 6.8 2.1 8.9 8.2
10 Norway 7.0 7.6 1.5 9.1 8.2
12 Austria 7.5 7.7 2.5 10.2 8.1
13 Portugal 5.6 7.4 2.8 10.2 7.7
14 New Zealand 5.9 7.0 2.0 9.0 7.2
15 UK 5.6 7.1 2.1 9.3 7.1
15 Ireland 8.3 5.8 1.7 7.5 7.1
15 Finland 6.3 5.9 1.6 7.5 7.1
18 Japan 6.5 6.6 1.4 8.0 7.0
19 Spain 5.3 5.9 2.3 8.2 6.8
Western countries
average
7.1 6.9 2.8 9.7 7.4
Average GDPHE 1980, 7.0; 1 s.d. =1.1
Average [1980–2005] 8.3; 1 s.d. =1.5
Current GDPHE average 9.7; 1 s.d.= 1.7
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Gender combined mortality rates (pm) by age 1979–1981 and ratio of change 1979–81 vs. 2003–2005
Countries current and previous ranks Adult (15–74) 15–34 35–54 Older (55–74)
1 USA – 5 9158 1222 4054 22,199
2001–2003 6959 919 3387 16,570
2002–2004 6739 913 3159 16,145
2004–2005 6660+1 s.d. 910 3149 15,919 + 1 s.d.
Ratio of change 0.73 0.74 0.78 0.72
2 Portugal – 13 7787 1107 3571 18,685
2001–2003 6483+1 s.d. 968 3140 15,341 + 1 s.d.
Ratio of change 0.83 0.87 0.88 0.82
3 Finland – 8 8437 944 3582 20,784
2004–2005 5692 642 2870 13,601
Ratio of change 0.68 0.68 0.80 0.65
4 Germany – 12 7887 803 3251 19,609
2003–2005 5492 464 2319 13,693
Ratio of change 0.70 0.58 0.71 0.70
5 UK – 3 9682 + 1 s.d. 679 3406 24,961 + 1 s.d.
2001–2003 6182 615 2317 15,453
2002–2004 5931 600 2272 14,920
2003–2005 5471 567 2207 13,638
Ratio of change 0.57 0.83 0.65 0.55
6 New Zealand – 4 9620 1086 3570 24,203 + 1 s.d.
2002–2004 5544 771 2108 13,754
Ratio of change 0.58 0.71 0.59 0.57
7 Ireland – 1 10374 + 1 s.d. 743 3618 26,738 + 1 s.d.
2003–2005 5433 559 1904 13,835
Ratio of change 0.52 0.75 0.53 0.52
8 France – 9 8162 1065 3825 19,591
2003–2005 5383 613 2794 12,742
Ratio of change 0.66 0.58 0.73 0.65
9 Netherlands – 11 7898 618 2881 20,196
2003–2005 5328 400 2022 13,563
Ratio of change 0.68 0.65 0.70 0.67
10 Austria – 2 9762 1098 4077 24,112
2004–2005 5302 581 2144 13,180
Ratio of change 0.54 0.53 0.53 0.55
11 Canada –10 8000 999 2759 20,239
2002–2004 5178 570 2045 12,918
Ratio of change 0.65 0.57 0.74 0.64
12 Italy – 7 8684 734 3690 22,127
2001–2003 5105 567 1909 12,837
Ratio of change 0.59 0.77 0.52 0.58
13 Norway – 14 7505 745 2794 18,976
2003–2005 5098 628 1921 12,746
Ratio of change 0.68 0.84 0.69 0.67
14 Greece –16 7200 709 2435 18,455
2003–2005 4970 572 2040 12,302
(Continued)
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5Portugal and Switzerland, whereas 15 other
countries, including the UK, had substantially
(P <0.001) greater reductions than the USA.
UK vs. other countries: With regard to ‘adult’
mortality rates, ﬁve countries had greater mor-
tality rate reductions than the UK, while 11 other
countries had signiﬁcantly lower falls than the
UK, including the USA (Table 4).
With respectto‘older’mortality rates,Australia,
Austria, Ireland, Italy and New Zealand had
signiﬁcantly greater falls than the UK, who in
turn had signiﬁcantly bigger reductions than
Canada, Finland, France, Germany, Greece,
Japan, Netherlands, Norway, Portugal, Spain,
Switzerland and the USA.
Cost-effectiveness: the average
GDPHE – ‘adult’ and ‘older’ reduced
mortality rate ratios
The GDPHE: Reduce mortality rate ratios were cal-
culated by dividing the level of reduced mortality
rate by the average GDPHE.
Table 5 shows the results, ranked by the
GDPHE: ‘older’ (55–74) ratios.
The biggest ratios, indicating the greatest
cost-effectiveness, were in Ireland, UK and
New Zealand at 1:1817, 1:1490 and 1:1451,
respectively.
The narrowest ratios were in Switzerland
(1:347), Portugal (1:434) and the USA (1:515).
Thus Ireland, the UK and New Zealand had
almost three times the cost-effectiveness ratio of
the lowest three countries, in effect doing more
with proportionately less over the period.
However, rates can obscure the reality of pro-
portion of lives saved as exempliﬁed in translating
the UK and USA reduced rates into numbers of
people.
There are now 176,258 fewer ‘adult’ deaths in
the UK, which includes 127,631 fewer ‘older’
people than in 1979–1981 and 543,467 fewer
‘adult’ deaths in the USA, of which 307,983 were
‘older’ (55–74).
Discussion
Principal ﬁnding
The null working hypotheses can be rejected, as
the majority of other countries had signiﬁcantly
Table 2
Continued
Countries current and previous ranks Adult (15–74) 15–34 35–54 Older (55–74)
Ratio of change 0.69 0.81 0.84 0.67
15 Spain – 18 6499 – 1 s.d. 758 2900 18,348
2003–2005 4913 527 2180 12,032
Ratio of change 0.76 0.70 9.75 0.66
16 Australia – 6 9154 1016 3577 22,869
2001–2003 4826 656 1843 11,966
Ratio of change 0.53 0.65 0.52 0.53
17 Sweden – 15 7496 732 2923 18,834
2003–2005 4373 – 1 s.d. 462 1741 10,915 – 1 s.d.
Ratio of change 0.58 0.63 0.60 0.58
18 Switzerland – 9 5651 – 1 s.d. 823 2229 13,901 – 1 s.d.
2003–2005 4353 – 1 s.d. 653 1735 10,672 –1 s.d.
Ratio of change 0.77 0.79 0.78 0.77
19 Japan – 17 6782 – 1 s.d. 646 2802 16,890 – 1 s.d.
2003–2005 4182 – 1 s.d. 386 1770 10,390 – 1 s.d.
Ratio of change 0.62 0.6 0.63 0.62
Adult average was 8236 pm, 1 s.d.= 1201; current 5144 pm, 1 s.d.= 593
‘Older’ average 20,607 pm, 1 s.d. =3507 pm; current average 12,950 pm, 1 s.d.= 1386 pm
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6greater mortality rate reductions than the USA in
relation to both ‘adult’ and ‘older’ people, which
was generally the converse for the UK.
While in regard to the cost-effectiveness ratios,
only Portugal and Switzerland had worse
GDPHE:mortality rate ratios than the USA
showing that most other countries achieved more
with proportionately less.
Conversely, apart from Ireland the UK GDPHE:
reduced mortality rate ratios were substantially
better than any other country.
Nonetheless, every country had reduced it
mortality, and while there are many inter-related
factors that would contribute to these improve-
ments
9–13 these results are grounds for cautious
satisfaction.
Strengths and weaknesses
The source of data can be said to be the most
authoritative available in regard to mortality
rates but there are a number of qualifying
aspects that must be recognized.
First, it is that the USA is a continent and on a
range of socioeconomic and health factors there is
considerable variation between the States, not least
marked ethnic variations.
1,5 Although most
Western countries have regional economic vari-
ations, few have the variation of, for example,
California, which is larger than many Western
countries, and Arkansas, et cetera. A second factor
is life or cultural styles of the USA, in particular
the availability of ﬁrearms, which impacts upon
mortality rates such as homicide and suicide, far
more than any other Western country,
16,17 placing
an extra burden upon USA services. Finally, it
might be argued that as the dominant healthcare
system in America is ‘private’ via direct insurance
means that as a substantial minority of Americans
are not fully insured
1,18 therefore such people are
n o tr e a l l yp a r to ft h e i rc a r es y s t e ma st h e ya r en o t
in the ‘treatment’ group or in the actual system.
However, they are part of the wider medical
s y s t e m ,i . e .M e d i c a r ea n dM e d i a i da sw e l la st h e
concern of public health policy.
1 However, it
should be noted that in countries like Switzerland,
with high average GDPHE and below the mean
mortality rate, such countries can only have rela-
tively marginal improvements, whereas the USA,
with high average GDPHE but relatively high
initial mortality rate, had greater opportunity for
improvement, but their mortality rate worsened
and is now signiﬁcantly above the Western mean.
This is exactly the opposite of the relatively most
‘cost-effective’ countries, such as Ireland and the
UK, whose mortality rate was initially higher than
the mean but is within the mean of the other
Western countries. Hence the argument that for
such countries there may be even greater gains if
t h e i rG D P H Ew a sc l o s e rt ot h a to ft h ea v e r a g eo f
the countries reviewed, although it is recognized
there will, as in the case of Switzerland and Japan
a point of relative diminishing returns, where
greater expenditure only brings marginal
improvements.
Meaning of the study
USA results
The USA results are perhaps not a surprise as a
recent UNICEF report showed that in terms of
material wellbeing the USA general population
was below OECD inequality average, being 23rd
out of 24 countries reviewed; were 19th, with
Table 3
USA vs. other Western countries’ average adult deaths (chi-square
results and P value)
Country 1980–
1981 vs. latest
year
Average 15–74 mortality
rate USA vs. other
Western countries
55–74 mortality rate
USA vs. other Western
countries
Australia 235.5 (<0.0001) 544.1 (<0.0001)
Austria 155.1 (<0.0001) 327.8 (<0.0001)
Canada 28.61 (<0.0001) 72.93 (<0.0001)
Finland 10.1783 (<0.005) 56.49 (<0.0001)
France 16.83 (<0.001) 40.16 (<0.0001)
Germany 3.3173 (<0.1) t 3.0444 (<0.1) t
Greece 4.5373 (<0.05) 21.93 (<0.0001)
Ireland 200.2 (<0.0001) 490.88 (<0.0001)
Japan 42.16 (<0.0001) 8.35 (<0.0001)
Italy 117.0 (<0.0001) 278.4 (<0.0001)
New Zealand 110.4 (<0.0001) 275.8 (<0.0001)
Netherlands 9.8398 (<0.005) 18.63 (<0.001)
Norway 7.9041 (<0.005) 17.91 (<0.001)
Portugal 11.56 (<0.001) 40.50 (<0.0001)
Spain 2.4341
† 32.57 (<0.0001)
Sweden 78.27 (<0.001) 179.8 (<0.0001)
Switzerland 4.9716 (<0.05) 17.01 (<0.001)
UK 78.98 (<0.0001) 220.0 (<0.0001)
The USA had greater reduced mortality rates than other countries
†P value not signiﬁcant
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7regard to educational wellbeing, and for health
and wellbeing 22nd, and currently the USA
child (0–14) mortality is the highest among
Western countries.
12 Consequently, on these
measures the US healthcare system is the least
effective and efﬁcient of Western countries and
probably reﬂects structural political and socioeco-
nomic factors.
How can the poor USA results be explained
bearing in mind the notion that market forces are
assumed to lead to greater effectiveness and pro-
ductive efﬁciency. On the other hand, Adam
Smith (1776), the protagonist of the ‘market’,
said that in some spheres, such as health and edu-
cation, the state could more effective than the
market alone.
19 One economic factor, long-known,
is that that these inefﬁciencies would be expected
within a dominant ‘Private’ healthcare system as
based mainly upon private insurance, what
might be called the uncertainty principle, that is
intrinsic to health, in terms of patient illnesses
there is asymmetric information, so the
‘unknowns’ can only be partially prepared by
the insurer, hence the built-in ‘uncertainty’, as
they are bound to have less information than the
‘customer’, who are accepted on an open assump-
tion of a modicum of healthiness.
19–22 Due to
asymmetric information insurers charge high pre-
miums in order to make up for a few individuals
that require unexpectedly very expensive
medical treatment. A relatively huge bureaucratic
burden is needed to monitor the costs, behaviour
and risks of customers, as well as the immense
legal costs required to control payment.
23 This
may be a factor contributing to the relatively
worse US clinical outcomes are these integral
market failures when applied to healthcare at a
national level. Another linked the problem is that
described as adverse selection, where those who
take out health insurance are more likely to be
those of greatest risk, so insurance companies
raise premiums, but relatively deprives the
person of average health as they ‘pay’ for the
less healthy, which can discourage those with
average health, the better bets, from taking out
insurance.
19–22 Indeed the problem of under-
insurance and the uninsured are another signiﬁ-
cant aspect of this market failure, adding to US
mortality.
11,13,18,23–25 Paradoxically therefore, a
mainly ‘Public’ health system, such asthe majority
of other countries, including the NHS, are at a
national level, likely to have less productive inefﬁ-
ciency, as it avoids the inherent market failures
related to proﬁt-making, necessary in the
‘Private’ insurance system. Although theoretically
a ‘Private’ system, such as the USA, relies on com-
petition to reduce costs, but because of these
inherent market failures of ‘asymmetric infor-
mation’ and ‘adverse selection’ factors, there will
always be inherent market weaknesses within
the whole system,
20–22 which may go some way
to explain the differences in the observed cost-
effectiveness results of the USA and the UK.
UK results
With regard to the ‘better than expected’ UK clini-
cal outcomes, it must not be forgotten that despite
the UK having among the biggest reductions in
mortality, UK ‘adult’ rates are ﬁfth highest
among Western countries and their ‘older’ rates
sixth highest, so there can be no grounds for com-
placency, although starting signiﬁcantly above the
Table 4
UK vs. other countries’ mortality rates (chi-square results and
P value)
Country 1980–
1981 vs. latest
year
Average 15–74 mortality
rate USA vs. other
Western countries
55–74 mortality rate
USA vs. other Western
countries
Australia 57.36 (<0.0001) 121.9 (<0.0001)
Austria 13.02 (<0.001) 0.0036
†
Canada 5.1372 (<0.05) 18.41 (<0.001)
Finland 29.93 (<0.0001) 69.88 (<0.0001)
France 39.84 (<0.0001) 61.21 (<0.0001)
Germany 45.02 (<0.0001) 157.9 (<0.0001)
Greece 38.26 (<0.0001) 86.51 (<0.0001)
Ireland 26.84 (<0.0001) 52.97 (<0.0001)
Japan 2.5176
† 16.07 (<0.001)
Italy 9.447 (<0.005) 18.52 (<0.001)
New Zealand 6.7019 (<0.01) 11.5505 (<0.001)
Netherlands 28.86 (<0.0001) 100.6 (<0.0001)
Norway 31.22 (<0.0001) 97.51 (<0.0001)
Portugal 137.1 (<0.0001) 206.4 (<0.0001)
Spain 93.34 (<0.0001) 67.53 (<0.0001)
Sweden 0.3305
† 0.1234
†
Switzerland 101.6 (<0.0001) 299.5 (<0.0001)
USA 78.98 (<0.0001) 220.0 (<0.0001)
The UK had greater mortality rate reduction than other Western
countries
†P value not signiﬁcant
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On the other hand, compared with most other
countries, unlike the USA, the UK achieved sig-
niﬁcantly bigger clinical reductions and with
below average and current GDPHE economic
input.
Implications for clinicians and
policymakers
It is acknowledged that the precise reasons of the
differences between countries’ outcomes are
beyond the competence of this paper and would
require nation-speciﬁc analysis. Overall however,
it is reiterated that every country has seen major
falls in its death rates and longevity has increased
over the past 25 years,
5 so despite the huge sums
going to health, on reﬂection, this health expendi-
ture has been well spent, especially when these
rates are translated into the numbers of people
who have not died, as more than 170 thousand
people in the UK and more than half a million in
America are alive today, who would not have
been 25 years ago.
The UK results appear to be at odds with the
recent high proﬁle debate about cancer survival
rates,
26 yet in terms of actual cancer mortality
rates <74, rather than the more ambiguous ‘survi-
val’ rates,
27,28 the UK had better results than the
USA, which appears to be linked by major
additional funds going to cancer care.
29–31
It is hoped these results might be a boost to
patients and their families in every Western
country but especially those using the NHS, and
that some recognition goes to UK frontline staff,
who over the past 25 years, have achieved more
with relatively less.
Unanswered questions and
future research
This study cannot account for the variables that
may have contributed to the differences between
Table 5
GDPHE: reduced death ratios 1980–2005 (ranked by greater GDPHE: 55–74 mortality rate ratio)
Country and rank
Average 15–74
reduced deaths (rpm)
Average GDPHE:
death ratio
55–74 Deaths
reduced (rpm)
55–74 Deaths:
GDPHE ratio
1 Ireland 4941 1:696 12,903 1:1817
2U K
Numbers saved
3951
162,264
1:557 10,576
121,190
1:1490
3 New Zealand 4076 1:566 10,449 1:1451
4 Austria 4460 1:551 11,194 1:1382
5 Australia 4328 1:521 10,903 1:1314
6 Italy 3579 1:436 9290 1:1133
7 Finland 2255 1:318 7183 1:1012
8 Japan 2600 1:380 6500 1:929
9 Spain 1586 1:233 6316 1:929
10 Sweden 3123 1:355 7919 1:900
11 Canada 2822 1:324 7321 1:841
12 Netherlands 2570 1:306 6633 1:790
13 France 2779 1:316 6849 1:778
14 Norway 2407 1:294 6230 1:766
15 Greece 2230 1:265 6423 1:765
16 Germany 2395 1:247 5916 1:610
17 USA
Numbers saved
2498
415,702
1:205 6286
238,642
1:515
18 Portugal 1304 1:169 3344 1:434
19 Switzerland 1298 1:140 3229 1:347
UK 1979–1981 population (age bands) 41.069 m and 11.459 m
USA 166.414 m and 37.964 m
rpm = rates per million
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9countries. In particular, to what degree might the
role of predominately public healthcare systems,
compared to the mainly private healthcare
system, inﬂuenced the results? Future research
should look at possible socioeconomic factors, in
particular the potential contribution of differential
levels of relative poverty and whether there are
variations between adult and children’s outcomes.
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